This Week in Cell

An international team led by René Bernards, with The Netherlands Cancer Institute and Agendia, explores the genetics of cancer treatment susceptibility and resistance, focusing first on ALK and EGF receptor tyrosine kinase inhibitor therapies. Using an RNA interference screen in a non-small cell lung cancer line carrying an EML4-ALK translocation, the researchers determined that knocking down a gene called MED12 confers resistance to an ALK-inhibiting drug called crizotinib.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."